SEPTRNA insider selling

What happened: Septerna insiders have been reducing their stakes in the company. On May 26, 2026, Chief People Officer Samira Shaikhly sold nearly 12,000 shares, valued at approximately $355,000, leaving her with a 6.3% direct ownership. Later, on June 22, 2026, another insider, Long, sold 15,000 shares, impacting 13.46% of his direct holdings. Meanwhile, Guggenheim initiated coverage of Septerna with a 'Buy' rating and a $52 price target on June 11.

Market impact: These insider sales could signal a shift in sentiment among Septerna's key stakeholders, potentially impacting investor confidence in the company. However, Guggenheim's bullish stance suggests that the company's fundamentals, particularly its potential first-in-class hypoparathyroidism treatment, may still be attractive to some investors.

What to watch next: Upcoming catalysts include Septerna's Q2 earnings report, scheduled for August 15, 2026, which will provide insights into the company's financial health and progress on its drug pipeline. Additionally, any further insider trading activity or changes in analyst ratings could provide additional color on the evolving sentiment towards Septerna.